TY - JOUR
T1 - Is [18F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer?
AU - De Cicco, Concetta
AU - Gilardi, Laura
AU - Botteri, Edoardo
AU - Fracassi, Silvia L V
AU - Di Dia, Giuseppina A.
AU - Botta, Francesca
AU - Prisco, Gennaro
AU - Lombardo, Dario
AU - Rotmensz, Nicole
AU - Veronesi, Umberto
AU - Paganelli, Giovanni
PY - 2013/2
Y1 - 2013/2
N2 - Background: We retrospectively investigated 18F-FDG uptake by the primary breast tumor as a predictor for relapse and survival. Patients and methods: We studied 203 patients with cT1-T3N0 breast cancer. Standardized uptake value (SUVmax), was measured on the primary tumor. After a median follow-up of 68 months (range 22-80), the relation between SUVmax and tumor factors, disease free-survival (DFS) and overall survival (OS) was investigated. Results: In the PET-positive patients, the median FDG uptake by the tumor was 4.7. FDG uptake was significantly related to tumor size, number of involved axillary nodes, grade, negative ER, high Ki-67 and HER2 overexpression. No distant metastases or deaths occurred in the PET-negative group. Five-year DFS was 97% and 83%, respectively in the PET-negative and PET-positive groups (P = 0.096). At univariate analysis, DFS was significantly lower in patients with SUVmax >4.7 compared to the patients with negative PET (P = 0.042), but not to the patients with SUVmax ≤4.7 (P = 0.106). At multivariable analysis, among PET-positive patients, SUVmax was not an independent prognostic factor for DFS (HR>4.7 vs ≤4.7: 1.02 (95% CI 0.45-2.31)). Five-year OS was 100% and 93%, respectively, in the PET-negative and PET-positive groups (P = 0.126). Conclusion: FDG uptake by the primary lesion was significantly associated with several prognostic variables, but it was not an independent prognostic factor.
AB - Background: We retrospectively investigated 18F-FDG uptake by the primary breast tumor as a predictor for relapse and survival. Patients and methods: We studied 203 patients with cT1-T3N0 breast cancer. Standardized uptake value (SUVmax), was measured on the primary tumor. After a median follow-up of 68 months (range 22-80), the relation between SUVmax and tumor factors, disease free-survival (DFS) and overall survival (OS) was investigated. Results: In the PET-positive patients, the median FDG uptake by the tumor was 4.7. FDG uptake was significantly related to tumor size, number of involved axillary nodes, grade, negative ER, high Ki-67 and HER2 overexpression. No distant metastases or deaths occurred in the PET-negative group. Five-year DFS was 97% and 83%, respectively in the PET-negative and PET-positive groups (P = 0.096). At univariate analysis, DFS was significantly lower in patients with SUVmax >4.7 compared to the patients with negative PET (P = 0.042), but not to the patients with SUVmax ≤4.7 (P = 0.106). At multivariable analysis, among PET-positive patients, SUVmax was not an independent prognostic factor for DFS (HR>4.7 vs ≤4.7: 1.02 (95% CI 0.45-2.31)). Five-year OS was 100% and 93%, respectively, in the PET-negative and PET-positive groups (P = 0.126). Conclusion: FDG uptake by the primary lesion was significantly associated with several prognostic variables, but it was not an independent prognostic factor.
KW - Biological markers
KW - Breast cancer
KW - FDG uptake
KW - PET/CT
KW - Prognosis
KW - SUV
UR - http://www.scopus.com/inward/record.url?scp=84871715926&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871715926&partnerID=8YFLogxK
U2 - 10.1016/j.breast.2012.05.009
DO - 10.1016/j.breast.2012.05.009
M3 - Article
C2 - 22704459
AN - SCOPUS:84871715926
VL - 22
SP - 39
EP - 43
JO - Breast
JF - Breast
SN - 0960-9776
IS - 1
ER -